Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07806916 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT)

Name: Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT) — clinical trial record (NCT07806916)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GREAT

StatusNot Yet Recruiting

PhasePhase 2

SponsorBeijing Tiantan Hospital

Started2026-09

View on ClinicalTrials.gov ↗

Beijing Tiantan Hospital

280 trials monitored

See 4 trials at risk

The goal of this clinical trial is to evaluate the safety and effectiveness of Efgartigimod in patients with Guillain-Barre syndrome (GBS). The main questions it aims to answer are: Is Efgartigimod a safe treatment option for GBS patients? Does treatment with Efgartigimod improve patient outcomes? Participants will: Take drug Efgartigimod or Intravenous Immunoglobulin during hospitalization Undergo six blood draws in six follow-up study visits to evaluate the concentration of IgG Keep a diary of their symptoms and drugs using at the same time

Trial Details

NCT Number	NCT07806916
Lead Sponsor	Beijing Tiantan Hospital
Conditions	Guillain-Barré Syndrome
Enrollment	110 participants
Start Date	2026-09
Primary Completion	2027-06 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-18